— Know what they know.
Not Investment Advice

RGNX NASDAQ

REGENXBIO Inc.
1W: +8.2% 1M: -27.7% 3M: -17.1% YTD: -50.3% 1Y: -32.5% 3Y: -65.8% 5Y: -81.3%
$6.35
-0.40 (-5.93%)
 
Weekly Expected Move ±21.1%
$3 $5 $6 $7 $8
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 25 · $328.3M mcap · 43M float · 2.57% daily turnover · Short 60% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
31.2 / 100
NoneWeakNarrowWide
Primary source: Cost Advantage  ·  ROIC: -152.3%  ·  5Y Avg: -104.2%
Cost Advantage ★
47
Intangibles
26
Switching Cost
31
Network Effect
28
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. RGNX has No discernible competitive edge (31.2/100). The business operates without significant structural advantages. The primary source of advantage is Cost Advantage. Negative ROIC of -152.3% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$12
Low
$14
Avg Target
$16
High
Based on 2 analysts since May 14, 2026 earnings
Analyst Recommendations
Strong Buy: 1Buy: 13Hold: 5Sell: 1Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$18.75
Analysts4
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-15 Morgan Stanley $17 $16 -1 +153.6% $6.31
2026-05-15 Barclays Eliana Merle $37 $12 -25 +92.2% $6.25
2026-03-09 H.C. Wainwright $32 $30 -2 +189.0% $10.38
2026-03-05 Morgan Stanley Judah Frommer $22 $17 -5 +95.0% $8.72
2026-02-10 H.C. Wainwright $34 $32 -2 +258.9% $8.91
2026-02-10 Robert W. Baird Brian Skorney Initiated $27 +202.7% $8.92
2026-02-10 UBS Initiated $18 +100.8% $8.96
2026-02-10 Goldman Sachs $38 $12 -26 +16.4% $10.31
2026-01-29 H.C. Wainwright Yi Chen $39 $34 -5 +195.1% $11.52
2026-01-27 Barclays Initiated $37 +175.9% $13.41
2025-12-19 Stifel Nicolaus $40 $45 +5 +233.1% $13.51
2025-12-15 Leerink Partners Mani Foroohar $24 $20 -4 +44.1% $13.88
2025-03-18 Leerink Partners Initiated $24 +207.7% $7.80
2025-01-07 RBC Capital Luca Issi $35 $30 -5 +258.9% $8.36
2024-11-15 Morgan Stanley Judah Frommer Initiated $22 +97.5% $11.14
2024-10-10 Raymond James Danielle Brill Initiated $18 +96.0% $9.19
2024-09-05 H.C. Wainwright Yi Chen $38 $39 +1 +242.9% $11.38
2024-06-24 Stifel Nicolaus Annabel Samimy Initiated $40 +212.7% $12.79
2024-06-07 Goldman Sachs Paul Choi Initiated $38 +176.2% $13.76
2024-05-15 H.C. Wainwright Yi Chen $36 $38 +2 +140.5% $15.80
2024-03-11 H.C. Wainwright Yi Chen Initiated $36 +57.5% $22.85
2024-03-08 RBC Capital Luca Issi Initiated $35 +53.8% $22.75

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

D+
May 22, 2026
DCF
1
ROE
1
ROA
1
D/E
1
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. RGNX receives an overall rating of D+. Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), D/E (1/5), P/E (1/5), P/B (1/5).
Rating Change History
DateFromTo
2026-01-15 C- D+

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

5 Grade D
Profitability
0
Balance Sheet
34
Earnings Quality
33
Growth
12
Value
27
Momentum
20
Safety
0
Cash Flow
30
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. RGNX scores highest in Balance Sheet (34/100) and lowest in Profitability (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
-3.90
Distress Zone
Piotroski F-Score
1/9
Beneish M-Score
7.38
Possible Manipulator
Ohlson O-Score
-2.08
Bankruptcy prob: 11.2%
Moderate
Credit Rating
B-
Score: 23.2/100
Trend: Deteriorating
Earnings Quality
OCF/NI: 0.81x
Accruals: -12.2%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. RGNX scores -3.90, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. RGNX scores 1/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. RGNX's score of 7.38 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. RGNX's implied 11.2% bankruptcy probability is elevated and warrants attention to the balance sheet. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. RGNX receives an estimated rating of B- (score: 23.2/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-1.15x
PEG
0.02x
P/S
3.74x
P/B
15.79x
P/FCF
-1.86x
P/OCF
EV/EBITDA
-2.00x
EV/Revenue
5.35x
EV/EBIT
-1.90x
EV/FCF
-1.99x
Earnings Yield
-66.01%
FCF Yield
-53.81%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. RGNX currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
1.175
EBT / EBIT
×
EBIT Margin
-2.811
EBIT / Rev
×
Asset Turnover
0.191
Rev / Assets
×
Equity Multiplier
2.536
Assets / Equity
=
ROE
-160.1%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. RGNX's ROE of -160.1% is driven by Asset Turnover (0.191), indicating efficient use of assets to generate revenue. A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$6.35
Median 1Y
$3.66
5th Pctile
$1.02
95th Pctile
$13.24
Ann. Volatility
70.3%
Analyst Target
$18.75
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Curran Simpson
President and Chief Executive Officer
$665,510 $777,448 $4,200,712
Patrick J. Christmas
EVP, Chief Strategy and Legal Officer
$520,903 $— $2,041,511
Stephen Pakola, M.D.
EVP, Chief Medical Officer
$543,987 $505,343 $1,799,546

CEO Pay Ratio

10147:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $4,200,712
Avg Employee Cost (SGA/emp): $414
Employees: 200,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
200,000
+56557.2% YoY
Revenue / Employee
$852
Rev: $170,441,000
Profit / Employee
$-969
NI: $-193,878,000
SGA / Employee
$414
Avg labor cost proxy
R&D / Employee
$1,141
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -35.1% -51.3% 22.4% 17.7% 15.9% 12.9% -43.8% -42.2% -42.8% -40.7% -63.7% -62.8% -58.2% -57.7% -79.5% -55.2% -61.5% -62.3% -1.1% -1.6% -1.60%
ROA -24.1% -35.2% 14.0% 11.1% 10.0% 8.1% -28.8% -27.8% -28.2% -26.8% -37.4% -37.0% -34.3% -33.9% -43.7% -30.3% -33.8% -34.2% -42.2% -63.1% -63.11%
ROIC 4.2% 6.5% 36.8% 29.7% 27.1% 23.3% -84.3% -82.6% -86.0% -84.0% -1.7% -1.7% -1.5% -1.5% -1.7% -1.2% -1.2% -1.1% -95.6% -1.5% -1.52%
ROCE -20.0% -29.7% 17.0% 14.3% 13.2% 11.4% -36.6% -35.6% -37.0% -35.7% -57.9% -57.3% -53.1% -52.8% -59.1% -38.2% -40.2% -37.4% -44.4% -73.7% -73.71%
Gross Margin 55.4% 54.2% 94.2% 29.3% 60.3% 50.6% 59.2% 78.5% 52.6% 57.2% 29.9% 45.8% 34.4% 48.8% 70.2% 96.1% 57.3% -1.1% 80.5% -73.2% -73.22%
Operating Margin -2.4% -1.9% 78.7% -3.2% -1.9% -2.7% -1.8% -3.5% -3.7% -2.2% -2.9% -4.0% -2.5% -2.6% -2.4% 13.6% -3.0% -1.8% -1.9% -13.0% -13.04%
Net Margin -2.6% -1.9% 73.8% -3.5% -2.1% -2.8% -1.9% -3.5% -3.6% -2.1% -2.8% -4.1% -2.4% -2.5% -2.4% 6.8% -3.3% -2.1% -2.2% -14.1% -14.09%
EBITDA Margin -2.2% -1.6% 79.4% -3.1% -1.8% -2.5% -1.6% -3.1% -3.3% -1.9% -2.6% -3.7% -2.2% -2.3% -1.8% 20.9% -2.6% -1.5% -1.7% -13.0% -13.04%
FCF Margin -87.3% -1.7% 26.7% 28.3% 23.2% 24.6% -2.1% -2.3% -2.4% -2.3% -2.5% -2.3% -2.2% -2.2% -2.1% -55.5% -58.2% -65.9% -74.1% -2.7% -2.69%
OCF Margin -44.0% -82.6% 44.6% 41.8% 34.3% 32.9% -1.8% -2.1% -2.2% -2.2% -2.4% -2.2% -2.1% -2.2% -2.1% -53.6% -56.4% -64.0% -72.7% -2.7% -2.66%
ROE 3Y Avg snapshot only -1.42%
ROE 5Y Avg snapshot only -93.12%
ROA 3Y Avg snapshot only -47.73%
ROIC 3Y Avg snapshot only -1.32%
ROIC Economic snapshot only -56.10%
Cash ROA snapshot only -51.60%
Cash ROIC snapshot only -1.76%
CROIC snapshot only -1.78%
NOPAT Margin snapshot only -2.31%
Pretax Margin snapshot only -3.30%
R&D / Revenue snapshot only 2.60%
SGA / Revenue snapshot only 95.45%
SBC / Revenue snapshot only 29.63%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -11.37 -8.41 11.28 14.08 11.74 15.52 -3.50 -3.04 -3.17 -2.78 -3.00 -3.70 -2.46 -2.23 -1.73 -2.33 -2.41 -2.80 -3.84 -1.51 -1.148
P/S Ratio 10.24 19.19 3.06 3.01 2.20 2.38 8.71 7.49 8.97 7.28 8.75 11.11 6.65 6.32 4.72 2.35 2.71 3.09 4.37 5.00 3.738
P/B Ratio 4.37 4.73 1.89 1.86 1.39 1.50 1.90 1.59 1.69 1.40 2.53 3.09 1.90 1.71 1.51 1.42 1.63 1.92 7.25 4.28 15.792
P/FCF -11.73 -11.21 11.47 10.65 9.46 9.67 -4.12 -3.20 -3.69 -3.13 -3.46 -4.85 -3.04 -2.88 -2.24 -4.23 -4.66 -4.69 -5.90 -1.86 -1.858
P/OCF 6.87 7.20 6.41 7.23
EV/EBITDA -10.65 -7.82 6.05 7.00 4.92 6.24 -2.92 -2.34 -2.46 -1.94 -2.52 -3.28 -1.86 -1.59 -1.21 -1.76 -2.08 -2.88 -5.82 -2.00 -1.997
EV/Revenue 7.74 14.86 2.28 2.23 1.43 1.61 6.32 5.03 6.19 4.56 6.69 8.97 4.56 4.11 2.89 1.37 1.73 2.15 4.55 5.35 5.349
EV/EBIT -9.94 -7.44 6.39 7.52 5.33 6.87 -2.77 -2.20 -2.31 -1.81 -2.35 -3.06 -1.72 -1.48 -1.12 -1.55 -1.85 -2.55 -5.21 -1.90 -1.903
EV/FCF -8.87 -8.68 8.52 7.88 6.17 6.53 -2.99 -2.15 -2.54 -1.96 -2.64 -3.91 -2.09 -1.88 -1.37 -2.47 -2.98 -3.26 -6.14 -1.99 -1.987
Earnings Yield -8.8% -11.9% 8.9% 7.1% 8.5% 6.4% -28.5% -32.9% -31.5% -36.0% -33.4% -27.0% -40.7% -44.8% -57.8% -42.9% -41.5% -35.7% -26.0% -66.0% -66.01%
FCF Yield -8.5% -8.9% 8.7% 9.4% 10.6% 10.3% -24.3% -31.3% -27.1% -32.0% -28.9% -20.6% -32.9% -34.7% -44.6% -23.6% -21.5% -21.3% -17.0% -53.8% -53.81%
PEG Ratio snapshot only 0.020
Price/Tangible Book snapshot only 4.277
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 6.52 6.52 3.98 3.98 3.98 3.98 3.19 3.19 3.19 3.19 2.57 2.57 2.57 2.57 2.69 2.69 2.69 2.69 2.38 2.38 2.382
Quick Ratio 6.39 6.39 3.98 3.98 3.98 3.98 3.19 3.19 3.19 3.19 2.57 2.57 2.57 2.57 2.69 2.69 2.69 2.69 2.38 2.38 2.382
Debt/Equity 0.19 0.19 0.11 0.11 0.11 0.11 0.18 0.18 0.18 0.18 0.29 0.29 0.29 0.29 0.32 0.32 0.32 0.32 2.54 2.54 2.536
Net Debt/Equity -1.07 -1.07 -0.49 -0.49 -0.49 -0.49 -0.52 -0.52 -0.52 -0.52 -0.60 -0.60 -0.60 -0.60 -0.59 -0.59 -0.59 -0.59 0.30 0.30 0.296
Debt/Assets 0.10 0.10 0.08 0.08 0.08 0.08 0.11 0.11 0.11 0.11 0.16 0.16 0.16 0.16 0.18 0.18 0.18 0.18 0.58 0.58 0.575
Debt/EBITDA -0.62 -0.41 0.49 0.58 0.61 0.70 -0.39 -0.40 -0.39 -0.41 -0.37 -0.38 -0.41 -0.41 -0.41 -0.67 -0.63 -0.68 -1.96 -1.11 -1.108
Net Debt/EBITDA 3.44 2.28 -2.09 -2.46 -2.63 -2.99 1.10 1.14 1.11 1.15 0.78 0.79 0.85 0.85 0.77 1.25 1.17 1.27 -0.23 -0.13 -0.129
Interest Coverage -9.08 -9.06 6.38 5.46 4.97 4.42 -11.06 -12.60 -18.39 -25.57 -37.42 -41.81 -43.60 -50.89 -16.94 -7.19 -4.89 -3.22 -3.31 -8.90 -8.903
Equity Multiplier 1.87 1.87 1.46 1.46 1.46 1.46 1.61 1.61 1.61 1.61 1.84 1.84 1.84 1.84 1.79 1.79 1.79 1.79 4.41 4.41 4.410
Cash Ratio snapshot only 1.948
Debt Service Coverage snapshot only -8.483
Cash to Debt snapshot only 0.883
FCF to Debt snapshot only -0.907
Defensive Interval snapshot only 364.8 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.27 0.15 0.52 0.52 0.53 0.53 0.12 0.11 0.10 0.10 0.13 0.12 0.13 0.12 0.16 0.30 0.30 0.31 0.37 0.19 0.191
Inventory Turnover 8.05 7.43 9.87 11.94 12.53 12.34
Receivables Turnover 7.44 4.29 21.69 21.85 22.34 22.14 349.53 339.98 300.69 308.14 7.20 6.92 7.10 6.73 6.71 12.61 12.54 12.98 12.89 6.64 6.642
Payables Turnover 4.97 4.58 4.71 5.70 5.98 5.89 2.83 2.22 2.04 2.01 1.66 1.84 2.04 2.04 1.83 1.61 1.37 3.54 3.64 3.98 3.983
DSO 49 85 17 17 16 16 1 1 1 1 51 53 51 54 54 29 29 28 28 55 55.0 days
DIO 45 49 37 31 29 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 days
DPO 73 80 77 64 61 62 129 164 179 182 220 199 179 179 199 226 266 103 100 92 91.6 days
Cash Conversion Cycle 21 54 -24 -17 -16 -16 -128 -163 -177 -181 -169 -146 -127 -124 -145 -197 -237 -75 -72 -37 -36.7 days
Fixed Asset Turnover snapshot only 0.578
Cash Velocity snapshot only 0.382
Capital Intensity snapshot only 5.159
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 1.7% -35.7% 2.0% 2.0% 2.0% 4.2% -76.0% -76.9% -80.0% -79.3% -19.9% -20.9% -8.2% -15.1% -7.7% 80.7% 74.9% 91.3% 1.0% -44.0% -43.96%
Net Income -7.7% -1.3% 2.1% 1.8% 1.6% 1.3% -3.2% -3.7% -4.0% -4.5% 6.0% 3.7% 12.1% 8.3% 13.8% 39.4% 27.2% 25.5% 14.6% -83.9% -83.91%
EPS 5.6% -1.1% 2.0% 1.8% 1.6% 1.3% -3.2% -3.6% -4.0% -4.5% 7.5% 8.5% 24.4% 20.7% 25.5% 46.1% 28.4% 26.8% 16.1% -80.4% -80.43%
FCF -14.1% -18.9% 2.6% 2.2% 1.8% 1.7% -2.9% -2.9% -3.1% -3.0% 4.1% 22.7% 17.5% 20.1% 23.1% 56.2% 53.4% 42.5% 28.0% -1.7% -1.72%
EBITDA 17.8% -81.4% 2.8% 2.5% 2.2% 1.7% -2.4% -2.6% -2.7% -2.9% 2.0% -0.4% 10.2% 6.8% 17.2% 48.3% 40.6% 44.9% 32.8% -92.1% -92.11%
Op. Income 12.7% -95.7% 2.3% 2.1% 1.9% 1.5% -2.6% -2.9% -3.2% -3.4% -2.0% -2.4% 8.0% 7.0% 13.8% 40.3% 33.3% 36.4% 30.3% -63.1% -63.13%
OCF Growth snapshot only -1.78%
Asset Growth snapshot only -2.78%
Equity Growth snapshot only -60.43%
Debt Growth snapshot only 2.18%
Shares Change snapshot only 1.93%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y -2.8% -19.7% 29.1% 75.9% 1.1% 95.5% 47.4% 28.2% 16.9% -11.8% -16.4% -17.7% -18.0% -3.3% -43.8% -30.8% -31.5% -30.5% 14.8% -7.1% -7.13%
Revenue 5Y 80.8% 66.2% 1.5% 1.5% 1.2% 1.2% 61.1% -5.1% -11.2% -11.2% -16.2% -0.1% 10.2% 5.6% 18.8% 24.7% 20.8% 2.2% 2.0% -10.8% -10.83%
EPS 3Y 4.1%
EPS 5Y
Net Income 3Y 8.6%
Net Income 5Y
EBITDA 3Y 24.4%
EBITDA 5Y
Gross Profit 3Y -8.4% -30.2% 26.1% 72.7% 1.0% 93.9% 29.2% 18.2% 7.5% -19.4% -25.7% -29.9% -31.7% -15.0% -53.7% -33.7% -33.2% -42.1% 15.7%
Gross Profit 5Y 78.2% 56.2% 1.6% 1.6% 1.3% 1.2% -11.7% -18.0% -17.6% -25.3% -12.5% -5.2% -10.2% 9.0% 24.3% 21.9% -7.0% -5.4%
Op. Income 3Y 22.0%
Op. Income 5Y
FCF 3Y 11.2% 2.3%
FCF 5Y
OCF 3Y 26.1% 1.3%
OCF 5Y
Assets 3Y 52.8% 52.8% 27.0% 27.0% 27.0% 27.0% 18.7% 18.7% 18.7% 18.7% -6.8% -6.8% -6.8% -6.8% -25.2% -25.2% -25.2% -25.2% -18.4% -18.4% -18.38%
Assets 5Y 26.2% 26.2% 45.2% 45.2% 45.2% 45.2% 33.2% 33.2% 33.2% 33.2% 1.1% 1.1% 1.1% 1.1% -1.3% -1.3% -1.3% -1.3% -8.5% -8.5% -8.55%
Equity 3Y 27.3% 27.3% 14.5% 14.5% 14.5% 14.5% 4.7% 4.7% 4.7% 4.7% -6.2% -6.2% -6.2% -6.2% -30.2% -30.2% -30.2% -30.2% -41.6% -41.6% -41.62%
Book Value 3Y 19.6% 18.1% 9.9% 8.3% 8.5% 8.5% -0.8% -0.7% -0.6% 0.5% -11.1% -9.0% -11.5% -11.5% -33.5% -34.3% -34.2% -34.2% -45.0% -45.2% -45.16%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.24 0.19 0.53 0.65 0.66 0.61 0.31 0.10 0.05 0.02 0.07 0.00 0.01 0.01 0.01 0.00 0.00 0.06 0.01 0.22 0.218
Earnings Stability 0.31 0.33 0.11 0.03 0.00 0.01 0.12 0.24 0.26 0.28 0.43 0.28 0.21 0.21 0.28 0.18 0.13 0.13 0.26 0.34 0.341
Margin Stability 0.91 0.84 0.90 0.92 0.92 0.84 0.00 0.86 0.85 0.81 0.73 0.75 0.72 0.69 0.73 0.77 0.74 0.69 0.80 0.39 0.393
Rev. Growth Consistency 1.00 0.00 1.00 1.00 1.00 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.50 0.50 0.50 0.50 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.97 0.50 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.50 0.50 0.50 0.50 0.94 0.84 0.89 0.90 0.94 0.50 0.500
Earnings Smoothness
ROE Trend -0.19 -0.40 0.42 0.41 0.46 0.48 -0.48 -0.43 -0.40 -0.27 -0.66 -0.64 -0.57 -0.56 -0.18 0.07 -0.02 -0.05 -1.03 -2.10 -2.102
Gross Margin Trend -0.10 -0.26 0.12 0.10 0.11 0.18 -0.31 -0.21 -0.21 -0.11 -0.16 -0.27 -0.30 -0.34 -0.03 0.23 0.29 -0.00 0.01 -0.62 -0.619
FCF Margin Trend 0.99 -0.46 2.22 1.88 1.69 1.56 -1.98 -2.11 -2.11 -1.60 -1.61 -1.26 -1.09 -1.15 0.22 1.76 1.73 1.60 1.58 -1.27 -1.269
Sustainable Growth Rate 22.4% 17.7% 15.9% 12.9%
Internal Growth Rate 16.3% 12.5% 11.1% 8.8%
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.49 0.36 1.64 1.95 1.83 2.15 0.74 0.86 0.80 0.83 0.83 0.74 0.79 0.76 0.76 0.53 0.50 0.58 0.64 0.81 0.806
FCF/OCF 1.98 2.07 0.60 0.68 0.68 0.75 1.15 1.11 1.08 1.07 1.05 1.03 1.02 1.01 1.01 1.03 1.03 1.03 1.02 1.01 1.011
FCF/Net Income snapshot only 0.815
CapEx/Revenue 43.3% 88.5% 17.9% 13.5% 11.1% 8.3% 27.3% 22.4% 18.5% 14.4% 11.0% 6.6% 4.0% 2.9% 2.9% 1.9% 1.8% 1.9% 1.4% 3.0% 2.99%
CapEx/Depreciation snapshot only 0.225
Accruals Ratio -0.12 -0.22 -0.09 -0.11 -0.08 -0.09 -0.07 -0.04 -0.06 -0.04 -0.06 -0.10 -0.07 -0.08 -0.10 -0.14 -0.17 -0.14 -0.15 -0.12 -0.122
Sloan Accruals snapshot only -0.051
Cash Flow Adequacy snapshot only -89.058
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio 0.0% 0.0% 0.0% 0.0%
FCF Payout Ratio 0.0% 0.0% 0.0% 0.0%
Total Payout Ratio 0.0% 0.0% 0.0% 0.0%
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.0% 0.0% 0.00%
Net Buyback Yield -13.3% -12.3% -15.2% -0.2% -0.4% -0.4% -0.3% -0.4% -0.3% -1.0% -0.9% -14.4% -23.3% -24.8% -33.6% 0.0% -0.0% -29.0% -0.1% -0.3% -0.29%
Total Shareholder Return -13.3% -12.3% -15.2% -0.2% -0.4% -0.4% -0.3% -0.4% -0.3% -1.0% -0.9% -14.4% -23.3% -24.8% -33.6% 0.0% -0.0% -29.0% -0.1% -0.3% -0.29%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.04 1.03 0.91 0.88 0.87 0.85 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 1.11 1.11 0.84 0.82 0.80 0.77 1.09 1.08 1.05 1.04 1.03 1.02 1.02 1.02 1.06 1.14 1.20 1.31 1.30 1.17 1.175
EBIT Margin -0.78 -2.00 0.36 0.30 0.27 0.23 -2.28 -2.28 -2.68 -2.52 -2.85 -2.93 -2.65 -2.78 -2.57 -0.88 -0.94 -0.84 -0.87 -2.81 -2.811
Asset Turnover 0.27 0.15 0.52 0.52 0.53 0.53 0.12 0.11 0.10 0.10 0.13 0.12 0.13 0.12 0.16 0.30 0.30 0.31 0.37 0.19 0.191
Equity Multiplier 1.46 1.46 1.60 1.60 1.60 1.60 1.52 1.52 1.52 1.52 1.70 1.70 1.70 1.70 1.82 1.82 1.82 1.82 2.54 2.54 2.536
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-3.42 $-4.98 $2.90 $2.36 $2.10 $1.70 $-6.47 $-6.22 $-6.30 $-5.93 $-5.99 $-5.69 $-4.76 $-4.70 $-4.46 $-3.07 $-3.41 $-3.44 $-3.75 $-5.53 $-5.53
Book Value/Share $8.89 $8.86 $17.34 $17.80 $17.73 $17.67 $11.92 $11.88 $11.86 $11.75 $7.08 $6.82 $6.16 $6.14 $5.10 $5.05 $5.04 $5.02 $1.99 $1.96 $0.40
Tangible Book/Share $8.89 $8.86 $17.34 $17.80 $17.73 $17.67 $11.92 $11.88 $11.86 $11.75 $7.08 $6.82 $6.16 $6.14 $5.10 $5.05 $5.04 $5.02 $1.99 $1.96 $1.96
Revenue/Share $3.79 $2.18 $10.67 $11.03 $11.23 $11.10 $2.60 $2.52 $2.23 $2.26 $2.05 $1.90 $1.76 $1.66 $1.64 $3.05 $3.03 $3.12 $3.29 $1.68 $1.68
FCF/Share $-3.31 $-3.74 $2.85 $3.12 $2.61 $2.73 $-5.50 $-5.92 $-5.42 $-5.26 $-5.19 $-4.34 $-3.85 $-3.64 $-3.45 $-1.69 $-1.76 $-2.06 $-2.44 $-4.51 $-4.51
OCF/Share $-1.67 $-1.81 $4.76 $4.61 $3.85 $3.66 $-4.79 $-5.35 $-5.01 $-4.94 $-4.96 $-4.22 $-3.78 $-3.59 $-3.40 $-1.63 $-1.71 $-2.00 $-2.40 $-4.46 $-4.46
Cash/Share $11.19 $11.16 $10.38 $10.65 $10.61 $10.58 $8.42 $8.39 $8.38 $8.30 $6.26 $6.02 $5.44 $5.42 $4.61 $4.56 $4.56 $4.54 $4.45 $4.39 $2.87
EBITDA/Share $-2.76 $-4.15 $4.02 $3.51 $3.27 $2.86 $-5.64 $-5.43 $-5.60 $-5.32 $-5.44 $-5.18 $-4.33 $-4.29 $-3.90 $-2.38 $-2.52 $-2.32 $-2.57 $-4.49 $-4.49
Debt/Share $1.71 $1.70 $1.97 $2.02 $2.01 $2.00 $2.19 $2.18 $2.18 $2.16 $2.03 $1.95 $1.76 $1.76 $1.61 $1.59 $1.59 $1.59 $5.03 $4.97 $4.97
Net Debt/Share $-9.48 $-9.46 $-8.41 $-8.63 $-8.60 $-8.57 $-6.23 $-6.21 $-6.20 $-6.14 $-4.23 $-4.07 $-3.68 $-3.66 $-3.00 $-2.97 $-2.97 $-2.95 $0.59 $0.58 $0.58
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score -3.899
Altman Z-Prime snapshot only -8.085
Piotroski F-Score 4 2 7 6 7 6 2 2 1 2 1 1 2 2 5 5 5 4 4 1 1
Beneish M-Score -2.81 -2.03 13.45 -0.72 -1.28 -1.52 4.44 -3.33 -2.96 -3.07 -2.85 -3.18 -3.08 -3.38 -3.81 -0.26 -4.06 -4.37 -2.90 7.38 7.380
Ohlson O-Score snapshot only -2.075
ROIC (Greenblatt) snapshot only -78.33%
Net-Net WC snapshot only $-1.32
EVA snapshot only $-216100830.00
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only B-
Credit Score 49.92 50.24 85.86 85.85 75.45 75.48 39.05 38.85 38.57 38.57 31.30 31.49 31.20 31.31 30.99 30.79 30.60 30.54 23.28 23.25 23.247
Credit Grade snapshot only 16
Credit Trend snapshot only -7.538
Implied Spread (bps) snapshot only 900.000
Industry Credit Rank snapshot only 11
Sector Credit Rank snapshot only 11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms